by Peter Ciszewski | Jul 27, 2020
Diego Cadavid, MD of Fulcrum Therapeutics provides an update on the Phase 2 Clinical Trial testing the safety and efficacy of losmapimod to treat facioscapulohumeral muscular dystrophy (FSHD). FSHD is a rare, progressive musculoskeletal disease in which persons...
by Peter Ciszewski | Jul 25, 2020
The U.S. Food and Drug Administration (FDA) has approved Tecartus (brexucabtagene autoleucel), a chimeric antigen receptor (CAR) T cell therapy, to treat adults with mantle cell lymphoma (MCL). MCL is a rare form of non-Hodgkin’s lymphoma in which B-cells become...
by Peter Ciszewski | Jul 24, 2020
Federico Grossi, MD, Chief Medical Officer at Apellis Pharmaceuticals, discusses the pathophysiology of paroxysmal nocturnal hemoglobinuria (PNH). Dr. Grossi also describes the typical symptoms and diagnostic journal that PNH patients must endure. PNH is a...
by Peter Ciszewski | Jul 23, 2020
Ashish Sagrolikar, Chief Commercial Officer of Zogenix, discusses the recent approval of Fintepla (fenfluramine) to reduce the frequency of seizures in Dravet patients 2 years of age or older. Dravet syndrome, according to the NIH, is a severe form of epilepsy...
by Peter Ciszewski | Jul 22, 2020
Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation, provides an overview of her organization. The Lymphoma Research Foundation is a nonprofit organization dedicated to funding education and research of different types of lymphoma. The...
